| International Session（Symposium）2(JSGE・JGES) |
| Thu. November 21st 14:00 - 16:30 Room 11: Portopia Hotel South Wing Topaz |
| HIGHLY BIOAVAILABLE CURCUMIN (THERACURMIN®) FOR CROHN’S DISEASE: RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL | |||
| Ken Sugimoto1, Akira Andoh2, Hiroyuki Hanai3 | |||
| 1First Department of Medicine, Hamamatsu University School of Medicine, 2Department of Medicine, Shiga University of Medical Science, 3Center for Gastroenterology & IBD Research, Hamamatsu South Hospital | |||
|
|||
|
|||
| Background and aims: This study investigated whether highly-absorbed curcumin (Theracurmin®) can be clinically effective when administered to patients with active Crohn's disease (CD). Methods: Theracurmin® (curcumin as 360 mg/day) or placebo was administered for 12 weeks in patients diagnosed with mild to moderate CD (180 ≤ CDAI < 450). Evaluation items included the Crohn’s Disease Activity Index (CDAI), Simple Endoscopic Score for Crohn's Disease (SES-CD), rate of improvement in intestinal stenosis or anal lesions, blood levels of inflammatory markers, and severity of anemia. Result: Theracurmin® or placebo was administered to 31 patients with CD. Clinical remission (CDAI <150) was achieved in 35% at 4 weeks and in 40% at 8 and 12 weeks in the Theracurmin® group, with 0% at 4, 8, and 12 weeks in the placebo group; these values were significantly higher in the Theracurmin® group than in the placebo group. The SES-CD was significantly improved at week 12 compared with that at week 0 in the Theracurmin® group, but there was no significant difference between weeks 0 and 12 in the placebo group. There were no serious side effects in the Theracurmin® or placebo groups throughout the entire observation period. Conclusion: Administration of Theracurmin® resulted in significant clinical and endoscopic improvement in patients with active CD. |
|||
|
Index Term 1: Crohn's disease Index Term 2: Theracurmin |
|||
| Page Top | |||